The colorectal cancer (CRC) is a malignancy arising from uncontrolled cell growth in the colon or rectum epithelium. CRC is caused from the hyperactivity of Wnt/ β-catenin signaling pathway. The central signal transducer of the pathway is the transcription factor, β-catenin. As coactivator, BCL9 protein binds to β-catenin and contributes to the transcriptional activation of Wnt target genes leading to the colon cancer. BCL9-β-catenin interaction is a validated therapeutic target. Our project aim the discovery of small-molecule inhibitors of BCL9-β-catenin could stop the metastasis. A number of validated hits have been identified by experimental screening. My aim was the creation of a pharmacophore model by using validated hits by ligand-based tool, Phase from Schrodinger package and validation of the Phase protocol and identification of possible binding modes of hits by molecular docking tool, Glide from Schrodinger package. However any common pharmacophore could be identified from hits.